Compound Evidence File
#EC-2026-0055
Tesofensine
Filed under Oral Tablets. The bureau holds 122 laboratory returns for this compound from 43 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
43 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 19 Mar 2026 | 7 Jul 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 11 May 2026 | 2 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 10.0 | 9.9 | 10.0 | 1 Feb 2026 | 5 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 10.0 | 9.9 | 10.0 | 15 May 2026 | 19 Aug 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 10.0 | 10.0 | 20 Mar 2026 | 9 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 10.0 | 10.0 | 10.0 | 20 May 2026 | 10 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 10.0 | 10.0 | 10.0 | 5 Jan 2026 | 2 Jul 2026 |
| Huayi BiotechnologyCASE #VI-2026-0243 | X | 1 | 10.0 | 10.0 | 10.0 | 13 Feb 2025 | 13 Feb 2025 |
| Risynth BioCASE #VI-2026-0672 | X | 1 | 10.0 | 10.0 | 10.0 | 13 Jun 2025 | 13 Jun 2025 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 19 Apr 2026 | 10 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 8 May 2026 | 8 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 9 Mar 2026 | 13 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 9 Feb 2026 | 26 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 10.0 | 3 May 2026 | 10 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 9.9 | 9.9 | 10.0 | 17 May 2026 | 22 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 10.0 | 17 Apr 2026 | 17 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 10.0 | 10 Mar 2026 | 2 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 9.9 | 9.9 | 10.0 | 7 May 2026 | 17 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 9.9 | 1 Apr 2026 | 2 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 15 Nov 2025 | 12 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 5 May 2026 | 1 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 10.0 | 25 Jun 2026 | 15 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 9.9 | 9.9 | 9.9 | 7 Aug 2026 | 17 Aug 2026 |
| Peptide PartnersCASE #VI-2026-0295 | X | 1 | 9.2 | 9.2 | 9.2 | 21 May 2025 | 21 May 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.6 | 7.4 | 9.6 | 23 May 2026 | 23 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 8.5 | 6.0 | 10.0 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 8.5 | 6.8 | 9.6 | 25 May 2026 | 25 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 8.0 | 7.5 | 8.2 | 23 May 2026 | 23 May 2026 |
| Zen PeptidesCASE #VI-2026-0940 | X | 1 | 7.8 | 7.8 | 7.8 | 11 Jun 2025 | 11 Jun 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 3 | 7.7 | 7.1 | 8.7 | 24 May 2026 | 24 May 2026 |
| LSPLCASE #VI-2026-0523 | X | 3 | 7.5 | 6.9 | 8.0 | 17 Dec 2024 | 25 May 2026 |
| Forever Young PharmacyCASE #VI-2026-0654 | X | 1 | 7.5 | 7.5 | 7.5 | 13 Jun 2025 | 13 Jun 2025 |
| NextGen HealthCASE #VI-2026-0604 | X | 1 | 7.2 | 7.2 | 7.2 | 9 Jun 2025 | 9 Jun 2025 |
| HK PeptidesCASE #VI-2026-0140 | X | 3 | 7.0 | 5.0 | 8.9 | 14 Jan 2025 | 23 May 2026 |
| Xingtai Pukelai Technology CoCASE #VI-2026-0850 | X | 1 | 7.0 | 7.0 | 7.0 | 21 May 2025 | 21 May 2025 |
| Anlv BiotechnologyCASE #VI-2026-0110 | X | 1 | 6.9 | 6.9 | 6.9 | 16 Mar 2025 | 16 Mar 2025 |
| Alpha-GenCASE #VI-2026-0905 | X | 3 | 5.6 | 5.0 | 6.2 | 13 Jun 2025 | 21 May 2026 |
| Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 | E | 3 | 5.3 | 3.3 | 7.3 | 28 Mar 2025 | 24 May 2026 |
| Xianhong Tong XHT PeptidesCASE #VI-2026-0997 | X | 1 | 4.5 | 4.5 | 4.5 | 3 Jun 2025 | 3 Jun 2025 |
| PRIVATECASE #VI-2026-0635 | X | 1 | 0.0 | 0.0 | 0.0 | 3 Jun 2025 | 3 Jun 2025 |
| PepKitsCASE #VI-2026-0320 | X | 1 | 0.0 | 0.0 | 0.0 | 27 Feb 2025 | 27 Feb 2025 |
Open any subject to view the batch-level evidence for Tesofensine alone.